Acurx Pharmaceuticals (NASDAQ:ACXP) operates within the biotech industry focusing on the development of new antibiotics to combat bacterial infections, specifically targeting the treatment of Clostridioides difficile infections (CDI). The company is committed to advancing its lead candidate, ibezapolstat, through clinical trials aiming to offer a novel solution to address the rising global concern of antibiotic resistance. With a project pipeline designed to innovate and improve upon current treatment methodologies, Acurx Pharmaceuticals is actively working towards overcoming the challenges in treating bacterial infections effectively. Their objective remains steadfast in delivering breakthrough therapies to patients in need while striving for excellence in antibiotic drug development.